^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD163 expression

i
Other names: CD163, CD163 Molecule, M130, Scavenger Receptor Cysteine-Rich Type 1 Protein M130, Hemoglobin Scavenger Receptor, CD163 Antigen, SCARI1, MM130, Macrophage-Associated Antigen
Entrez ID:
Related biomarkers:
3d
CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov)
P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2023
Trial completion date • Trial primary completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
|
KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan
13d
Exosome-transmitted podoplanin promotes tumor-associated macrophage-mediated immune tolerance in glioblastoma. (PubMed, CNS Neurosci Ther)
This investigation underscores that EVsPDPN derived from glioblastoma cells contributes to M2 macrophage-mediated immunosuppression and is a potential prognostic marker and therapeutic target in glioblastoma.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • CD68 (CD68 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • GFAP (Glial Fibrillary Acidic Protein)
|
MHC-II expression • CD163 expression
15d
Single-cell RNA sequencing analysis of vestibular schwannoma reveals functionally distinct macrophage subsets. (PubMed, Br J Cancer)
Macrophages form an important component of VS stroma. scRNAseq reveals three distinct subsets of macrophages in the VS tissue which may have differing roles in the pathogenesis of VS.
Journal
|
AREG (Amphiregulin) • CD163 (CD163 Molecule) • SPP1 (Secreted Phosphoprotein 1) • PLCG2 (Phospholipase C Gamma 2) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • IL1B (Interleukin 1, beta) • ALOX15 (Arachidonate 15-Lipoxygenase) • PLAUR (Plasminogen Activator, Urokinase Receptor)
|
AREG expression • CD163 expression
1m
ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms. (PubMed, Cancer Immunol Res)
In a human tumor explant histoculture system, dual ILT2/ILT4 blockade increased CXCL9 secretion, downregulated CD163 expression, and increased the expression of M1 macrophage, IFN-γ, and cytolytic T cell gene signatures. Thus, we have revealed distinct contributions of ILT2 and ILT4 to myeloid cell biology and provide proof-of-concept data supporting the combined blockade of ILT2 and ILT4 to therapeutically induce optimal myeloid cell reprogramming in the tumor microenvironment.
Journal
|
IFNG (Interferon, gamma) • CD163 (CD163 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD86 (CD86 Molecule)
|
CD163 expression
1m
Gabapentin attenuates cardiac remodeling after myocardial infarction by inhibiting M1 macrophage polarization through the peroxisome proliferator-activated receptor-γ pathway. (PubMed, Eur J Pharmacol)
Gabapentin attenuates cardiac remodeling by inhibiting inflammation via peroxisome proliferator-activated receptor-γ activation and preventing calcium overload.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
CD163 expression
1m
Journal
|
CD163 (CD163 Molecule) • MRC1 (Mannose Receptor C-Type 1) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CD163 expression
2ms
Programmed Cell Death Ligand 1 Expression in CD163+ Tumor-associated Macrophages in Cancer Gland Rupture Microenvironment. (PubMed, Appl Immunohistochem Mol Morphol)
High PD-L1 expression in CD163+ TAMs is associated with poor overall survival. Therefore, blocking PD-L1 in CD163+ TAMs can be used as a target for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule)
|
PD-L1 expression • PD-L1 overexpression • CD163 expression
|
PD-L1 IHC 22C3 pharmDx
2ms
The therapeutic effect of phellopterin on colitis-associated cancer and its effects on TLR4/NF-κB pathway and macrophage M2 polarization. (PubMed, Cell Mol Biol (Noisy-le-grand))
The effect of phellopterin intervention on CAC was dose-dependent. In conclusion, phellopterin can improve the symptoms and inflammatory response of CAC and inhibit the occurrence of colon cancer (CC) by inhibiting M2 polarization of macrophages and activation of the TLR4/NF-κB pathway.
Journal
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
|
CD163 expression
2ms
Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms. (PubMed, BMC Pulm Med)
In stage IA NSCLC, a low concentration of IFN-γ promotes the polarization of TAMs to the M2 phenotype in the TME model by upregulating the expression of IDO1, promoting the viability of cancer cells, inhibiting the viability of T cells and NK cells, and thus establishing an immune microenvironment conducive to tumor progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
BCL2 expression • CD20 expression • IDO1 expression • IFNG expression • BAX expression • CD163 expression • MRC1 expression
2ms
Niosomal hesperidin attenuates the M1/M2-macrophage polarization-based hepatotoxicity followed chlorpyrifos -induced toxicities in mice. (PubMed, Pestic Biochem Physiol)
The ameliorative effects of Hesp and Nio + Hesp may be at least in part due to their antioxidant and anti-inflammatory properties. These findings showed that both M1- and M2-macrophages contributed to the development of hepatic lesions induced by CPF and provided information about macrophage activation, indicating the importance of analysis of macrophage phenotypes for hepatotoxicity based on M1/M2-polarization which can be downregulated by niosomal nesperidin.
Preclinical • Journal
|
CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
CD163 overexpression • CD163 expression
3ms
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Dec 2023 --> Feb 2024
Trial initiation date
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
ARG1 overexpression • CD163 expression
|
Keytruda (pembrolizumab) • cisplatin • gemcitabine
3ms
Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer. (PubMed, Medicine (Baltimore))
Drug sensitivity analysis revealed that these hub genes could be potential therapeutic targets for the treatment of HGSOC. We constructed a risk model for the overall survival and explored the potential mechanism of monocyte in HGSOC.
Journal
|
CD163 (CD163 Molecule)
|
CD163 expression
3ms
Correlation between F-FDG PET-derived parameters and quantitative pathological characteristics of soft tissue sarcoma. (PubMed, Quant Imaging Med Surg)
F-FDG uptake was positively correlated with the quantitative pathological features of soft tissue tumors. SUV may be a meaningful method reflecting the level of M2 macrophage infiltration and may provide additional valuable information for preclinical evaluation of STS.
Journal • FDG PET
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
|
CD163 expression
3ms
Comprehensive analysis of the role of netrin G1 (NTNG1) in hepatocellular carcinoma cells. (PubMed, Eur J Pharmacol)
Additionally, an EMT inhibitor attenuated the expression levels of EMT-related markers and counteracted the effects of NTNG1 overexpression in liver cancer cells. This study is the first to identify NTNG1 as a potential therapeutic target in HCC, promoting tumor development and progression by regulating EMT.
Journal
|
CD163 (CD163 Molecule) • CDH2 (Cadherin 2)
|
CD163 expression
4ms
Hypoxia-regulated exosomes mediate M2 macrophage polarization and promote metastasis in chondrosarcoma. (PubMed, Aging (Albany NY))
Further analysis revealed that M2 macrophages polarized by exosomes expressed arginase-1 and feedback to chondrosarcoma cells to promote migration. These results suggest that chondrosarcoma cells secrete more exosomes in a hypoxic microenvironment, and these hypoxia-derived exosomes induce the polarization of macrophages into an M2 phenotype, ultimately promoting the metastatic behavior of chondrosarcoma cells.
Journal
|
CD163 (CD163 Molecule) • ARG1 (Arginase 1) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
CD163 expression
4ms
Co-Occurrence of Clonally Related Follicular Lymphoma and Histiocytic Sarcoma (ASH 2023)
By applying single cell genomics analyses to a combined FL/HS biopsy, our study aims to understand the evolutionary relationship of HS arising from FL, particularly whether the HS arose from an early dormant clone (branched evolution) or from a late, prevalent Fl clone (linear evolution). Evidence of the former would strengthen the view that common progenitor cells (CPCs) in FL are capable of differentiating into myeloid and lymphoid malignancies.
IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • CREBBP (CREB binding protein) • BIRC3 (Baculoviral IAP repeat containing 3) • CD163 (CD163 Molecule) • S100A8 (S100 Calcium Binding Protein A8) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • CD68 (CD68 Molecule) • STAT2 (Signal transducer and activator of transcription 2)
|
BCL2 expression • MYC expression • BCL2 rearrangement • CD163 expression • STAT2 expression
4ms
Unlocking the link between haptoglobin polymorphism and noninfectious human diseases: insights and implications. (PubMed, Crit Rev Clin Lab Sci)
Therefore, the Hp1 allele may not necessarily confer advantages in all situations, and its effects may be context-dependent. This review highlights the current understanding of the role of Hp polymorphisms in cardiovascular disease, inflammatory bowel disease, cancer, transplantation, hemoglobinopathies, and polyuria.
Review • Journal
|
CD163 (CD163 Molecule)
|
CD163 expression
4ms
Rosai-Dorfman Disease of the Breast: A Clinicoradiologic and Pathologic Study. (PubMed, Hum Pathol)
Patients with RDD of the breast have an excellent prognosis after complete excision. KEW WORDS: Rosai-Dorfman disease; Breast Imaging-Reporting and Data System (BI-RADS); Immunohistochemistry; flow cytometry; kappa/lambda in situ hybridization.
Journal
|
BRAF (B-raf proto-oncogene) • CCND1 (Cyclin D1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
BRAF V600E • BRAF V600 • CCND1 expression • CD163 expression
4ms
Divergent Lineage Markers in Anaplastic Thyroid Carcinoma. (PubMed, Am J Surg Pathol)
Twenty tested cases showed retained SMARCA4 expression. We conclude that ATCs express a number of divergent lineage markers that can cause diagnostic dilemmas, as they are also features of other tumors in the differential diagnosis of high-grade midline neck malignancies.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD163 (CD163 Molecule) • NKX2-1 (NK2 Homeobox 1) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
|
BRAF V600E • BRAF V600 • NRAS Q61 • NRAS Q61R • CD163 expression • TTF1 negative
5ms
The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma. (PubMed, Cancers (Basel))
The interactions between TAMs in situ and, particularly, CD206 macrophages are highly relevant to patient outcomes. High-resolution technology is important for identifying the roles of macrophage populations in tissue specimens and identifying potential therapeutic candidates in MPM.
Journal
|
PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
CD163 expression
5ms
Prophylaxis of decidual CD68/CD163 macrophage disbalance in extracorporeal fertilized women. (PubMed, Heliyon)
In women who became pregnant as a result of in vitro fertilization, at 28-30 weeks of pregnancy, changes specific for pro-inflammatory phenotype of decidual macrophages were observed. Complex administration of vitamin D3, micronized progesterone and l-arginine aspartate lead to restoration of anti-inflammatory phenotype of decidual macrophages.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CD68 (CD68 Molecule)
|
CD163 expression
5ms
ZNF746 promotes M2 macrophage polarisation and favours tumour progression in breast cancer via the Jagged1/Notch pathway. (PubMed, Cell Signal)
Mechanistically, ZNF746 promoted the activation of the Jagged1/Notch pathway, and the Jagged1 siRNA-mediated blockade of this pathway prevented the tumour-promoting functions of ZNF746. In conclusion, this study uncovers the role of ZNF746 in promoting M2 macrophage polarisation and suggests that ZNF746 may be a promising therapeutic target for limiting BC progression.
Journal
|
CD163 (CD163 Molecule) • CSF1 (Colony stimulating factor 1) • CCL2 (Chemokine (C-C motif) ligand 2) • HES1
|
CD163 expression
5ms
SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer. (PubMed, Biochem Biophys Res Commun)
IL-6 treatment improved polarization of M2 subtypes and the expression of PD-1 in bone marrow-derived macrophages (BMDMs); whereas both aIL-6 and STAT3 inhibitor C188-9 suppressed the expression of PD-1 and SIRPα in BMDMs...Thereby, SIRPα and IL-6 form a positive feedback loop and regulate each other through STAT3 signaling in macrophages. The increased SIRPα/IL-6 axis may promote immune suppressive environment and lung cancer growth, which may be a potential target for clinical treatment.
Journal • PD(L)-1 Biomarker • IO biomarker
|
IL6 (Interleukin 6) • CD163 (CD163 Molecule) • MRC1 (Mannose Receptor C-Type 1) • SIRPA (Signal Regulatory Protein Alpha)
|
PD-1 expression • CD163 expression • IL6 expression
|
TTI-101 oral
5ms
CD84 (SLAMF5) As a Potential Target for Immunomodulation in Cutaneous T-Cell Lymphoma (CTCL) (ASH 2023)
Our preliminary data from this exploratory study indicate that CD84 may be a potential target to reduce immunosuppression in CTCL. Further studies are needed to explore the functions of CD84 as an immune receptor in CTCL TME and its therapeutic potential in CTCL.
PD(L)-1 Biomarker • IO biomarker • Immunomodulating
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule)
|
PD-L1 expression • PD-1 expression • 84-gene expression signature • CD163 expression • CD4 expression
5ms
Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas (ASH 2023)
Therefore, we concluded that XPO1 inhibition indirectly impairs T-cell lymphoma growth and survival by depleting LAM, which are a dependency in these lymphomas.
IO biomarker
|
SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • XPO1 (Exportin 1) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • ITGAM (Integrin, alpha M)
|
CD163 expression
|
Xpovio (selinexor)
5ms
Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort (ESMO-IO 2023)
Conclusions In these preliminary analyses in the IMMUcan study, correlations between mIF and RNAseq data unveil biological processes potentially responsible for different immune infiltration patterns in HER2+ BC. Additional analyses are ongoing and further validation is warranted.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PTEN (Phosphatase and tensin homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • ITGAX (Integrin Subunit Alpha X)
|
PD-L1 expression • HER-2 positive • HER-2 expression • CD163 expression
5ms
The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma (ESMO-IO 2023)
Immune check points genes were also influenced by LIF expression including CTLA4 (ρ = 0.25, P < .0001) and LAG3 (ρ = 0.21, P < .0001). Conclusions LIF upregulation corelates with poor prognosis in ccRCC and induces an immune suppressed microenvironment.
IO biomarker
|
IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD163 (CD163 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • CCR8 (C-C Motif Chemokine Receptor 8) • LIF (LIF Interleukin 6 Family Cytokine)
|
LAG3 expression • CTLA4 expression • CD163 expression
5ms
Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study. (ESMO-IO 2023)
No significant correlations between baseline circulating IL-8 and the other two GS, VEGF or CD163 expression were observed. Conclusions In our study, elevated baseline circulating IL-8 was not only significantly associated with higher levels of other circulating inflammatory markers, but also with increased expression of the myeloid inflammation gene signature at tumor level in mRCC pts.
Clinical • Gene Signature • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD163 (CD163 Molecule)
|
CXCL8 elevation • VEGFA expression • CD163 expression • CXCL8 expression
|
Opdivo (nivolumab)
6ms
Effect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model. (PubMed, Cell Biochem Funct)
Besides late-stage tumour necrosis, none of the other results were statistically significant. This study demonstrates that 2-ME treatment has an antitumour effect on late-stage BC, however, with no increase in survival rate, whereas the treatment failed to demonstrate any benefit in early-stage BC.
Preclinical • Journal
|
CD163 (CD163 Molecule)
|
CD163 expression
|
Panzem (2-methoxyestradiol)
6ms
A Study of Adipose Tissue in Adaptive Responses to Exercise (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD163 (CD163 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1) • LEP (Leptin)
|
CD163 expression • IL6 expression • MRC1 expression
6ms
A Multiomics Analysis of the Close Connection between Intratumoral Microbiota and Immune Cell Infiltration in Colorectal Cancer. (PubMed, Int J Radiat Oncol Biol Phys)
We found specific intratumoral bacterial clusters that were related to tumor stage and location, and the clusters were strongly associated with tumor immune infiltration and patient prognosis. Our findings may provide new viewpoint for future research between intratumoral microbiota, metabolism pathway and tumor microenvironment.
Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-1 expression • CD163 expression • FOXP3 expression
7ms
Correlation of tumor-associated macrophage infiltration in glioblastoma with magnetic resonance imaging characteristics: a retrospective cross-sectional study. (PubMed, Quant Imaging Med Surg)
Age, location of the tumor, degree of tumor enhancement, ADC value, and TERT mutation status were associated with macrophage infiltration. These findings may serve as an effective tool for characterizing the tumor microenvironment in patients with Gb.
Observational data • Retrospective data • Journal • MRI
|
TERT (Telomerase Reverse Transcriptase) • CD163 (CD163 Molecule)
|
TERT mutation • IDH wild-type • CD163 expression • CD68 positive
7ms
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. (PubMed, Blood Adv)
The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. Here, high sCD163 was associated with both shorter PFS (HR 3.48 95% CI: 1.42-8.54) and shorter OS (HR 4.33 95% CI: 1.32-14.2), showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify MCL patients with a very good prognosis.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • CD163 (CD163 Molecule)
|
CD163 expression
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
7ms
Apoptosis-related Prognostic Factors in Advanced Colorectal Cancer Determined Using Tissue Microarrays. (PubMed, Anticancer Res)
A lower apoptosis percentage at the invasive front is associated with a poorer prognosis. CRC cases with a poor prognosis can be identified by evaluating apoptosis and CD163 expression in the invasive front.
Journal • Metastases
|
TP53 (Tumor protein P53) • CD163 (CD163 Molecule)
|
TP53 expression • CD163 expression
7ms
Multiomics Analysis Revealed the Close Connection between Intratumoral Microbiota and Immune Cell Infiltration in Colorectal Cancer (ASTRO 2023)
We found specific intratumoral bacterial clusters that were related to tumor stage and location, and the clusters were strongly associated with tumor immune infiltration and patient prognosis. Our findings may provide new viewpoint for future research between intratumoral microbiota, metabolism pathway and tumor microenvironment.
PD(L)-1 Biomarker • IO biomarker • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-1 expression • CD163 expression • FOXP3 expression
7ms
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers (clinicaltrials.gov)
P2, N=27, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
New P2 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
ARG1 overexpression • CD163 expression
|
Keytruda (pembrolizumab) • cisplatin • gemcitabine
7ms
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer. (PubMed, Cancer Res Commun)
After olaparib upregulation of PD-L1 and macrophages, suggests that combinatorial treatment might be beneficial. Our WOO study demonstrates that preoperative olaparib results in a reduction in Ki67, upregulation of PD-L1 CPS, and induction of protumor features of macrophages in HNSCC.
P2 data • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • CD80 (CD80 Molecule)
|
CD163 expression
|
Lynparza (olaparib) • cisplatin • Imfinzi (durvalumab)
7ms
miR-148b inhibits M2 polarization of LPS-stimulated macrophages by targeting DcR3 (PubMed, Zhonghua Yu Fang Yi Xue Za Zhi)
The results of flow cytometry showed that DcR3 could reverse the promoting effect of miR-148b on the CD86/CD163 ratio of macrophages (P<0.05). miR-148b inhibits the expression of DcR3, thereby inhibiting M2 polarization in LPS-stimulated macrophage cells.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • CD86 (CD86 Molecule) • MIR148B (MicroRNA 148b)
|
CD163 expression
8ms
Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment. (PubMed, Front Oncol)
Our results showed that the 4-culture tumor spheroids better resembled some critical features of patients' PDAC TIME than monoculture tumor spheroids. Using the proposed human 3D spheroid model for therapy testing at the preclinical stage may reveal pitfalls of chemo- and immuno-therapies to help the development of better anti-tumor therapies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD163 (CD163 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL2 (Chemokine (C-C motif) ligand 2) • CD40 (CD40 Molecule) • MRC1 (Mannose Receptor C-Type 1)
|
CD163 expression